Skip to main content
Home

Syndicate contentCelebrex

Researchers make discovery in colon cancer prevention

CLEVELAND ? A new study finds that individuals who have low expression of the "Celebrex gene," 15-PGDH, are actually resistant to Celebrex treatment when used to prevent colon cancer.

Licorice compound offers new cancer prevention strategy

A chemical component of licorice may offer a new approach to preventing colorectal cancer without the adverse side effects of other preventive therapies, Vanderbilt University Medical Center researchers report.

NIH Halts Use of COX-2 Inhibitor in Large Cancer Prevention Trial

The National Institutes of Health (NIH) announced today that it has suspended the use of COX-2 inhibitor celecoxib (Celebrex? Pfizer, Inc.) for all participants in a large colorectal cancer prevention clinical trial conducted by the National Cancer Institute (NCI). The study, called the Adenoma Prevention with Celecoxib (APC) trial, was stopped because analysis by an independent Data Safety and Monitoring Board (DSMB) showed a 2.5-fold increased risk of major fatal and non-fatal cardiovascular events for participants taking the drug compared to those on a placebo.

Researchers Define Celebrex Method for Tumor Reduction

The anti-inflammatory drug Celebrex, or celecoxib, reduces tumor mass by encouraging cell death and discouraging both cell proliferation and the sprouting of new blood vessels that feed growing tumors, according to a study reported in the November issue of Molecular Cancer Research. The study suggests this drug one day might be used to prevent and even treat breast tumors. Celebrex, marketed by Pfizer Inc., is a member of the general family of drugs that target the COX-2, an enzyme that plays a major role in arthritis pain and inflammation.



About us

Science Blog was started in August 2002. It lives, breathes and eats press releases from research organizations around the globe. Most of what you read here are press releases from the outfits named in the stories themselves. Got a news story you think belongs here? Let's talk. The other half of the equation is blog posts from readers like you. So if you have an interest in science, please register and join others like you in an ongoing, vibrant dialog about what makes the world tick. Meantime, please take a minute to read our Privacy Policy and Site Disclaimer.




Premium Drupal Themes by Adaptivethemes